Laryngectomy plus postoperative radio(system)therapy versus primary radio(system) therapy for the treatment of locally advanced laryngeal and hypopharyngeal cancer – results from the University Clinical Cancer Registry Regensburg

References

• Krebs - Kehlkopfkrebs [cited 2023 Jul 8]. Available from: https://www.krebsdaten.de/Krebs/DE/Content/Krebsarten/Kehlkopfkrebs/kehlkopfkrebs_node.htm.
   Google Scholar
• Jansen L, Moratin J, Waldmann A, et al. Mundhöhlen- und pharynxkarzinome: inzidenz, mortalität und überleben in deutschland. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2021;64(8):941–950. doi: 10.1007/s00103-021-03368-z.
   PubMedGoogle Scholar
• Seiwert TY, Cohen EEW. State-of-the-art management of locally advanced head and neck cancer. Br J Cancer. 2005;92(8):1341–1348. doi: 10.1038/sj.bjc.6602510.
   PubMed Web of Science ®Google Scholar
• Blanchard P, Baujat B, Holostenco V, et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): a comprehensive analysis by tumour site. Radiother Oncol. 2011;100(1):33–40. doi: 10.1016/j.radonc.2011.05.036.
   PubMed Web of Science ®Google Scholar
• Forastiere AA, Goepfert H, Maor M, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med. 2003;349(22):2091–2098. doi: 10.1056/NEJMoa031317.
   PubMed Web of Science ®Google Scholar
• Forastiere AA, Zhang Q, Weber RS, et al. Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. J Clin Oncol. 2013;31(7):845–852. doi: 10.1200/JCO.2012.43.6097.
   PubMed Web of Science ®Google Scholar
• Ferreira N, Netto E, Fonseca L, et al. Surgery versus radiotherapy: long term outcomes of T1 glottic cancer. Rep Pract Oncol Radiother. 2020;25(6):860–866. Available from https://pubmed.ncbi.nlm.nih.gov/32982591/. doi: 10.1016/j.rpor.2020.08.007.
   PubMedGoogle Scholar
• Strojan P, Haigentz M, Bradford CR, et al. Chemoradiotherapy vs. total laryngectomy for primary treatment of advanced ­laryngeal squamous cell carcinoma. Oral Oncol. 2013;49(4):283–286. doi: 10.1016/j.oraloncology.2012.11.002.
   PubMed Web of Science ®Google Scholar
• Li R, Wang Q, Yan L, et al. Radiotherapy versus partial laryngectomy in the management of early glottic cancer with anterior commissure involvement: a propensity score matched study with 256 patients. Oral Oncol. 2021;116:105230. doi: 10.1016/j.oraloncology.2021.105230.
   PubMed Web of Science ®Google Scholar
• Tang Z-X, Gong J-L, Wang Y-H, et al. Efficacy comparison between primary total laryngectomy and nonsurgical organ-preservation strategies in treatment of advanced stage laryngeal cancer: a meta-analysis. Medicine (Baltimore). 2018;97(21):e10625. doi: 10.1097/MD.0000000000010625.
   PubMed Web of Science ®Google Scholar
• Patel SA, Qureshi MM, Dyer MA, et al. Comparing surgical and nonsurgical larynx-preserving treatments with total laryngectomy for locally advanced laryngeal cancer. Cancer. 2019;125(19):3367–3377. doi: 10.1002/cncr.32292.
   PubMed Web of Science ®Google Scholar
• Dyckhoff G, Warta R, Herold-Mende C, et al. Chemoradiotherapy but not radiotherapy alone for larynx preservation in T3. Considerations from a german observational cohort study. Cancers (Basel). 2021;13(14):3435. doi: 10.3390/cancers13143435.
   PubMed Web of Science ®Google Scholar
• Lin DJ, Goodfellow M, Ong J, et al. Treatment outcomes of laryngectomy compared to non-surgical management of T3 laryngeal carcinomas: a 10-year multicentre audit of 179 patients in the northeast of England. J Laryngol Otol. 2020;134(12):1103–1107. doi: 10.1017/S0022215120002704.
   PubMed Web of Science ®Google Scholar
• Rao KN, Pai PS, Dange P, et al. Survival outcomes in T3 ­laryngeal cancers: primary total laryngectomy vs. concurrent ­chemoradiation or radiation therapy—a meta-analysis. Biomedicines. 2023;11(8):2128. doi: 10.3390/biomedicines11082128.
   PubMed Web of Science ®Google Scholar
• Leitlinienprogramm Onkologie: larynxkarzinom [Internet] [cited 2023 Jul 8]. Available from: https://www.leitlinienprogramm-onkologie.de/leitlinien/larynxkarzinom/.
   Google Scholar
• Mehanna H, Robinson M, Hartley A, et al. Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial. Lancet. 2019;393(10166):51–60. doi: 10.1016/S0140-6736(18)32752-1.
   PubMed Web of Science ®Google Scholar
• Rischin D, King M, Kenny L, et al. Randomized trial of radiation therapy with weekly cisplatin or cetuximab in Low-Risk HPV-Associated oropharyngeal cancer (TROG 12.01) - a trans-Tasman radiation oncology group study. Int J Radiat Oncol Biol Phys. 2021;111(4):876–886. doi: 10.1016/j.ijrobp.2021.04.015.
   PubMed Web of Science ®Google Scholar
• Gillison ML, Trotti AM, Harris J, et al. Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG oncology RTOG 1016): a randomised, multicentre, non-inferiority trial. Lancet. 2019;393(10166):40–50. doi: 10.1016/S0140-6736(18)32779-X.
   PubMed Web of Science ®Google Scholar
• Stokes WA, Jones BL, Bhatia S, et al. A comparison of overall survival for patients with T4 larynx cancer treated with surgical versus organ-preservation approaches: a national cancer data base analysis. Cancer. 2017;123(4):600–608. doi: 10.1002/cncr.30382.
   PubMed Web of Science ®Google Scholar
• Argiris A, Lefebvre JL. Laryngeal preservation strategies in locally advanced laryngeal and hypopharyngeal cancers. Front Oncol. 2019;9:419. doi: 10.3389/fonc.2019.00419.
   PubMed Web of Science ®Google Scholar